A5021830366- Nuclear Receptors and Signaling
- Parkinson's Disease Mechanisms and Treatments
- Histone Deacetylase Inhibitors Research
- Nerve injury and regeneration
- Receptor Mechanisms and Signaling
- Neuropeptides and Animal Physiology
- Autism Spectrum Disorder Research
- Barrier Structure and Function Studies
- Pain Mechanisms and Treatments
- Genetics and Neurodevelopmental Disorders
- Muscle Physiology and Disorders
- Neuroendocrine regulation and behavior
- RNA Interference and Gene Delivery
- Neuroinflammation and Neurodegeneration Mechanisms
- Signaling Pathways in Disease
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Neurotransmitter Receptor Influence on Behavior
- S100 Proteins and Annexins
- RNA regulation and disease
- Tryptophan and brain disorders
- Stress Responses and Cortisol
University College Cork
2019-2025
Parkinson's disease (PD) is a neurodegenerative disorder characterised by nigrostriatal dopaminergic (DA) neurodegeneration. There critical need for neuroprotective therapies, particularly those that do not require direct intracranial administration. Small molecule inhibitors of histone deacetylases (HDIs) are in vitro and vivo models PD, however it unknown whether Class IIa-specific HDIs when administered peripherally. Here we show 6-hydroxydopamine (6-OHDA) treatment induces protein kinase...
Epigenetic modifications in neurodegenerative disease are under investigation for their roles progression. Alterations acetylation rates of certain Parkinson's (PD)-linked genes have been associated with the pathological progression this disorder. In light this, and given lack disease-modifying therapies PD, HDAC inhibitors (HDIs) consideration as potential pharmacological agents. The neuroprotective effects pan-HDACs some class-specific tested vivo vitro models varying outcomes. Here we...
Parkinson's disease is characterized by the intracellular accumulation of α-synuclein which has been linked to early dopaminergic axonal degeneration. Identifying druggable targets that can promote growth in cells overexpressing important order develop strategies for intervention. Class-IIa histone deacetylases (HDACs) have previously emerged as targets, however, it not known specific class-IIa HDACs should be targeted neurite neurons. To provide insight into this, we used gene co-expression...
Microglial cells are brain-specific macrophages that swiftly react to disruptive events in the brain. activation leads specific modifications, including proliferation, morphological changes, migration site of insult, and changes gene expression profiles. A change inflammatory status has been linked many neurodegenerative diseases such as Parkinson’s disease Alzheimer’s disease. For this reason, investigation quantification microglial is essential for better understanding their role...
Parkinson's disease (PD) is neurodegenerative disorder with the pathological hallmarks of progressive degeneration midbrain dopaminergic neurons from substantia nigra (SN), and accumulation spread inclusions aggregated α-synuclein (α-Syn). Since current PD therapies do not prevent neurodegeneration, there a need to identify therapeutic targets that can α-Syn-induced reductions in neuronal survival neurite growth. We hypothesised genes are normally co-expressed α-Syn gene (SNCA), whose...
Regulator of G-protein signalling 4 (RGS4) is a signal transduction protein that accelerates intrinsic GTPase activity Gαi/o and Gαq subunits, suppressing GPCR signalling. Here, we investigate whether RGS4 modulates nociceptin/orphanin FQ (N/OFQ) opioid (NOP) receptor if this modulation has relevance for l-Dopa-induced dyskinesia.HEK293T cells transfected with NOP, NOP/RGS4 or NOP/RGS19 were challenged N/OFQ the small-molecule NOP agonist AT-403, using D1-stimulated cAMP levels as readout....
Adenosine 5'-triphosphate (ATP) is the principal source of cellular energy, which essential for neuronal health and maintenance. Parkinson's disease (PD) other neurodegenerative disorders are characterised by impairments in mitochondrial function reductions ATP levels. Thus there a need to better understand biology intracellular regulators production, order inform development new neuroprotective therapies diseases such as PD. One regulator Zinc finger HIT-domain containing protein 1...
Background and purpose: Regulator of G-protein signal 4 (RGS4) is a transduction protein that accelerates intrinsic GTPase activity Gαi/o Gαq subunits, suppressing GPCR signaling. Here we investigate whether RGS4 modulates nociceptin/orphanin FQ opioid (NOP) receptor signaling this modulation has relevance for L-Dopa induced dyskinesia. Experimental approach: HEK293T cells transfected with NOP, NOP/RGS4 or NOP/RGS19 were challenged N/OFQ the small molecule NOP agonist AT-403, using...